

Figure 1




Figure 2







Figure 3

Immunolabeling for α -SMA



control



cCAF-treated







Figure 4






Figure 5




Figure 6






Figure 7




control (day 0)



cCAF (day 0)



control (day 3)



cCAF (day 3)





Figure 8




Figure 9






Figure 10

Summary of cCAF/Peptide effects on cXCR1




Figure 11